RT Journal Article
SR Electronic
T1 A prospective pilot study demonstrating non-invasive calibration-free glucose measurement
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.17.24312052
DO 10.1101/2024.08.17.24312052
A1 Rothenbühler, Martina
A1 Lizoain, Aritz
A1 Rebeaud, Fabien
A1 Perotte, Adler
A1 Stoffel, Marc
A1 DeVries, J. Hans
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.17.24312052.abstract
AB Glucose is an essential molecule in energy metabolism. Dysregulated glucose metabolism, the defining feature of diabetes, requires active monitoring to prevent significant morbidity and mortality. Current technologies for intermittent and continuous glucose measurement are invasive. Non-invasive glucose measurement would eliminate this barrier towards making glucose monitoring more accessible, extending the benefits from people living with diabetes to prediabetes and the healthy. We developed and investigated a spectroscopy-based system for measuring glucose non-invasively and without per-person calibration. Using data from a study including adults with insulin-treated diabetes, we constructed a computational model from a development cohort of 15 subjects and found a mean absolute relative difference of 14.5% in an independent validation cohort of five subjects. The correlation between the average model sensitivity by wavelength and the spectrum of glucose was 0.45 (p<0.001). Our findings suggest that spectroscopy-based non-invasive measurement of glucose without invasive calibration is possible.Competing Interest StatementThe authors Adler Perotte and Fabien Rebeaud are employed by Liom. The conflict of interest was managed by a strict separation of investigators involved in development versus validation.Clinical TrialNCT06272136Funding StatementThis study was funded by Liom.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol has been approved by the Ethikkommission der Ärztekammer Nordrhein, Düssedorf, Germany. The file ID is DE-23-0001503. Approval was obtained on Jan 25, 2024I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll validation data produced in the present work are contained in the manuscript